Authors: Le Balc’h P, Pinceaux K, Pronier C, Seguin P, Reizine F
PMID: 32859241 PMCID: PMC7453668 DOI: 10.1186/s13054-020-03252-3
Abstract
The SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome (ARDS) with prolonged mechanical ventilation (MV). Patients with coronavirus disease 2019 (COVID-19) associated ARDS usually met the diagnosis criteria for sepsis-associated immunosuppression as acquired infections, primarily bacterial and fungal co-infections [1], are frequently encountered. Such secondary infections are associated with late mortality. Herpesviridae reactivation is common in non-immunocompromised patients with prolonged MV and could be responsible for increased mortality and longer duration of MV in ICU [2, 3]. Although the diagnosis of Herpesviridae pulmonary infection is challenging and not consensual in critically ill patients, therapeutic strategies are available to reduce morbidity and mortality [4]. As viral co-infections in these patients remain poorly investigated, we aimed to describe Herpesviridae pulmonary reactivations in patients with COVID-19 ARDS.
Keywords: cytomegalovirus, Herpes simplex virus, COVID-19, SARS-CoV-2
